Suresnes, August 29, 2024 – 8am CET – Neovacs (Euronext Growth Paris : ALNEV), a preclinical-stage biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, is honored to be listed among the latest CNRS publications following the signing of a collaboration and research contract with Dr. Nathalie Mignet’s team, Director of Research at the CNRS (laboratory “Unité de Technologies Chimiques et Biologiques pour la Santé (‘UTCBS’)” of the CNRS, Université Paris Cité and INSERM), for the joint development of new lipid formulations for the delivery of messenger RNA (mRNA).
Read the article: Neovacs and UTCBS join forces for a therapeutic RNA vaccine against asthma | CNRS
As a reminder, in view of their complementary objectives and know-how, Neovacs and the UTCBS laboratory have signed a collaboration agreement, announced on June 17, 2024 (see press release), to jointly develop lipid formulations for the delivery of mRNAs to target proteins, both self and non-self, for human and veterinary use.
Neovacs will bear the costs of this new project, estimated at €100k, and will benefit from exclusive worldwide exploitation rights to the lipids used in the formulation of mRNA vaccines for humans and animals, for therapeutic and prophylactic use in all types of vaccines.
In addition to outlining this ambitious collaboration, the article is enriched by several testimonials from Vincent Serra, Neovacs’ Scientific Director.
ABOUT NEOVACS
Neovacs is a French biotechnology company with a dual R&D and investment activity. Its proprietary products are vaccine candidates developed from its kinoid® technology platform for lupus and allergies. The innovative approach uses the patient’s own immune system to regulate the harmful overproduction of proteins (active immunotherapy) such as IL-4/IL-13/IgE. At the same time, the Company leverages its in-house expertise to invest in innovative Biotech and Medtech companies with strong potential. For further information: www.neovacs.fr
Jérôme FABREGUETTES-LEIB Anne-Charlotte DUDICOURT
Investor Relations Financial Press Relations
neovacs@actus.fr acdudicourt@actus.fr
01 53 67 36 78 06 24 03 26 52
nvcs_cp_publication_cnrs_vdef
Translated with DeepL.com (free version)